Celtrix Appoints Malcolm J. McKay as vice president, regulatory affairs and quality assurance.SANTA CLARA, Calif.--(BUSINESS WIRE)--Aug. 26, 1996--Celtrix Pharmaceuticals Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CTRX CTRX Contractions (labor & delivery) ) announced today that Malcolm J. McKay, Ph.D., has joined the company as vice president, regulatory affairs and quality assurance. McKay was formerly director of quality assurance and quality control at COR Therapeutics. He also previously served for four years at Celtrix as director of quality assurance. "We are delighted to have Malcolm McKay back at Celtrix," said Andreas Sommer Sommer is a surname, from the German and Danish word for the season "summer". It may refer to:
At Celtrix, McKay will be responsible for regulatory strategies and procedures supporting human clinical studies of SomatoKine. Phase I human studies are in progress, and feasibility studies in target patient populations are expected to begin later this year, in preparation for Phase II studies. SomatoKine is initially targeted for the treatment of critically ill patients who require major surgery and are suffering from destructive metabolic processes. McKay, age 40, had been director of quality assurance and quality control at COR Therapeutics since 1995. He served as director of quality assurance at Celtrix from 1991 to 1995 and, before that, oversaw this function at Berlex Biosciences. He was a senior quality assurance engineer and senior process development scientist at Triton Biosciences. In addition, McKay served as group leader of technical support at Abbott Laboratories. He earned his Ph.D. in biochemistry at the University of London For most practical purposes, ranging from admission of students to negotiating funding from the government, the 19 constituent colleges are treated as individual universities. Within the university federation they are known as Recognised Bodies and was a postdoctoral fellow at the Medical College of Virginia History The school was founded in 1838 as the Medical Department of Hampden-Sydney College. It received an independent charter from the General Assembly in 1854 and became the Medical College of Virginia, and shortly thereafter transferred all its property to the Commonwealth . Celtrix is a biopharmaceutical company developing novel therapeutics for seriously debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction , degenerative conditions primarily associated with severe trauma, chronic diseases or aging. Company programs are focused on the use of SomatoKine, a novel IGF-BP3 complex, to treat destructive metabolic processes (catabolism catabolism (kətăb`əlĭz'əm), subdivision of metabolism involving all degradative chemical reactions in the living cell. ) in acute indications such as major surgery, organ damage/failure and traumatic injury. Potential chronic indications could include osteoporosis, chronic renal (kidney) failure, and wasting conditions associated with cancer and AIDS. Through strategic alliances with Celtrix, The Green Cross Corp. is developing SomatoKine for the treatment of osteoporosis in Japan, and Genzyme Corp. is developing TGF-beta-2 as part of a comprehensive approach to tissue repair and the treatment of systemic disease. CONTACT: Celtrix Pharmaceuticals Inc., Santa Clara Andreas Sommer, 408/988-2500 |
|
|||||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion